The novel antibody therapies market for advanced stage drugs is anticipated to grow at a CAGR of 36% by 2035, claims Roots Analysis

Owing to the recent approval of therapies, such as Elzonris®, Pluvicto®, there has been a substantial increase in the R&D activity to evaluate the use of novel antibody therapy candidates for the treatment of a variety of disease indications

For additional details, please visit https://www.rootsanalysis.com/....reports/novel-antibo or email sales@rootsanalysis.com